Amicus Therapeutics’ (FOLD) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $21.00 price target on the biopharmaceutical company’s stock.

Several other brokerages have also commented on FOLD. JPMorgan Chase & Co. boosted their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Bank of America lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Guggenheim lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Amicus Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $16.88.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $9.27 on Wednesday. The firm has a market capitalization of $2.77 billion, a P/E ratio of -27.26, a PEG ratio of 1.25 and a beta of 0.62. Amicus Therapeutics has a one year low of $8.78 and a one year high of $14.03. The company’s fifty day moving average is $9.77 and its two-hundred day moving average is $10.53. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,884,273.08. The trade was a 0.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 22,901 shares of company stock valued at $259,863. 2.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. OLD Second National Bank of Aurora purchased a new stake in Amicus Therapeutics in the 3rd quarter valued at about $26,000. Hazlett Burt & Watson Inc. grew its holdings in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares during the period. Blue Trust Inc. grew its holdings in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,831 shares during the period. Arcadia Investment Management Corp MI purchased a new stake in Amicus Therapeutics in the 3rd quarter valued at about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Amicus Therapeutics in the 3rd quarter valued at about $55,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.